Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Arcus Biosciences

Request full access

Exciting young company founded on a vision of creating new cancer therapeutics through the utilization of emerging insights in immunology

Hayward, United StatesFounded 2015Biotech & Life Sciences

About Arcus Biosciences

Arcus Biosciences is a biopharmaceutical company dedicated to developing innovative combination therapies to combat cancer. The company focuses on designing and advancing medicines that improve the lives of cancer patients. Arcus operates in the oncology market, primarily serving patients, healthcare providers, and research institutions. The business model revolves around conducting clinical trials to test the efficacy and safety of their drug candidates, which are then brought to market upon successful approval. Revenue is generated through partnerships, licensing agreements, and eventual sales of approved therapies. Arcus is committed to relentless research and development, leveraging cutting-edge science to create potential cures for cancer.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2018

Arcus Biosciences in the Hayward ecosystem

Live from Dealroom

The Arcus Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

15 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A9 investors entered at this stage

  • The Column Group
  • Celgene
  • GV
  • Invus
  • Novartis
  • Taiho Pharma
  • Foresite Capital
  • RTA Capital
  • SVB Leerink

Series B and later6 investors entered at this stage

Employees mapped 646 incl. 2 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 15 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Patents

Estimated portfolio value
$80M

63 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

See Arcus Biosciences on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.